Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds RSS Feed PharmiWeb Candidate Blog RSS Feed PharmiWeb Client Blog


Press Release

Shire plc : Director/PDMR Shareholding

Shire plc
Posted on: 09 Aug 17
  August 9, 2017 - Shire plc (LSE: SHP, NASDAQ: SHPG)   Notification of transaction by person discharging managerial responsibilities and person closely associated with them  
1. Details of the person discharging managerial responsibilities ("PDMR") / person closely associated them ("PCA")
a)NameKim Stratton / Peter Stratton
2. Reason for the notification
a)Position / statusHead of International Commercial (PDMR) / PCA of Kim Stratton
b)Initial notification / amendmentInitial notification
3. Details of the issuer, emission allowance participant, auction platform, auctioneer or auction monitor
a)NameShire plc
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a)Description of the financial instrument, type of instrument Shire plc Ordinary Shares of 5 pence each ("Ordinary Shares")


Identification codeISIN: JE00B2QKY057
b)Nature of the transactionTransfer of Ordinary Shares held by Kim Stratton to a joint account held by Kim Stratton and Peter Stratton and the pledge of such Ordinary Shares as security for a loan.
c)Price(s) and volume(s)Price(s)Volume(s)
d) Aggregated information

- Aggregated volume

- Price
N/A (single transaction)
e)Date of the transactionAugust 8, 2017
f)Place of the transactionOutside a trading venue

Oliver Strawbridge
Senior Assistant Company Secretary

For further information please contact:

Investor Relations   
Ian Karp +1 781 482 9018
Robert Coates +44 1256 894874
Lisa 617 588 8607
Debbi Ford   +1 617 949 9083


About Shire

Shire is the leading global biotechnology company focused on serving people with rare diseases. We strive to develop best-in-class products, many of which are available in more than 100 countries, across core therapeutic areas including Hematology, Immunology, Neuroscience, Ophthalmics, Lysosomal Storage Disorders, Gastrointestinal / Internal Medicine / Endocrine and Hereditary Angioedema; and a growing franchise in Oncology.

Our employees come to work every day with a shared mission: to develop and deliver breakthrough therapies for the hundreds of millions of people in the world affected by rare diseases and other high-need conditions, and who lack effective therapies to live their lives to the fullest.

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Shire plc via GlobeNewswire

Last updated on: 10/08/2017

Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.